{
    "id": "342374a0-645e-e49e-e063-6394a90a2498",
    "indications": "Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3)",
    "contraindications": "Hypertension: Initial adult dose is 10 mg once daily. Titrate up to 40 mg daily based on blood pressure response. Initiate patients on diuretics at 5 mg once daily (2.1) Pediatric patients with glomerular filtration rate > 30 mL/min/1.73 m 2 : Initial dose in patients 6 years of age and older is 0.07 mg per kg (up to 5 mg total) once daily (2.1) Heart Failure: Initiate with 5 mg once daily. Increase dose as tolerated to 40 mg daily (2.2) Acute Myocardial Infarction (MI): Give 5 mg within 24 hours of MI. Followed by 5 mg after 24 hours, then 10 mg once daily (2.3) Renal Impairment: For patients with creatinine clearance ≥ 10 mL/min and ≤ 30 mL/min, halve usual initial dose. For patients with creatinine clearance < 10 mL/min or on hemodialysis, the recommended initial dose is 2.5 mg (2.4)",
    "warningsAndPrecautions": "2.5 mg Tablets:white to off-white, capsule-shaped tablets, imprinted with ‘H 144’ on one side and plain on the other side.\n\n \n                  NDC 76420-340-30 Bottles of 30 tablets, with child-resistant closure (relabeled from NDC 43547-351-03)\n                  NDC 76420-340-60 Bottles of 60 tablets, with child-resistant closure (repackaged from NDC 43547-351-XX)\n                  NDC 76420-340-90 Bottles of 90 tablets, with child-resistant closure (repackaged from NDC 43547-351-XX)\n                  NDC 76420-340-01 Bottles of 100 tablets, with child-resistant closure (relabeled from NDC 43547-351-10)\n                  NDC 76420-340-05 Bottles of 500 tablets, with child-resistant closure (relabeled from NDC 43547-351-50)\n                  \n                     5 mg Tablets:yellow, capsule-shaped tablets, imprinted with ‘H 145’ on one side and plain on the other side.\n\n \n                  NDC 76420-341-30 Bottles of 30 tablets, with child-resistant closure (relabeled from NDC 43547-352-03)\n                  NDC 76420-341-60 Bottles of 60 tablets, with child-resistant closure (repackaged from NDC 43547-352-XX)\n                  NDC 76420-341-90 Bottles of 90 tablets, with child-resistant closure (repackaged from NDC 43547-352-XX)\n                  NDC 76420-341-01 Bottles of 100 tablets, with child-resistant closure (relabeled from NDC 43547-352-10)\n                  NDC 76420-341-00 Bottles of 1000 tablets, with child-resistant closure (relabeled from NDC 43547-352-11)\n                  \n                     10 mg Tablets:light pink, capsule-shaped tablets, imprinted with ‘H 146’ on one side and plain on the other side.\n\n \n                  NDC 76420-342-30 Bottles of 30 tablets, with child-resistant closure (relabeled from NDC 43547-353-03)\n                  NDC 76420-342-60 Bottles of 60 tablets, with child-resistant closure (repackaged from NDC 43547-353-XX)\n                  NDC 76420-342-90 Bottles of 90 tablets, with child-resistant closure (repackaged from NDC 43547-353-XX)\n                  NDC 76420-342-01 Bottles of 100 tablets, with child-resistant closure (relabeled from NDC 43547-353-10)\n                  NDC 76420-342-00 Bottles of 1000 tablets, with child-resistant closure (relabeled from NDC 43547-353-11)\n                  \n                     20 mg Tablets:dark pink, capsule-shaped tablets, imprinted with ‘H 147’ on one side and plain on the other side.\n\n \n                  NDC 76420-343-30 Bottles of 30 tablets, with child-resistant closure (relabeled from NDC 43547-354-03)\n                  NDC 76420-343-60 Bottles of 60 tablets, with child-resistant closure (repackaged from NDC 43547-354-XX)\n                  NDC 76420-343-90 Bottles of 90 tablets, with child-resistant closure (repackaged from NDC 43547-354-XX)\n                  NDC 76420-343-01 Bottles of 100 tablets, with child-resistant closure (relabeled from NDC 43547-354-10)\n                  NDC 76420-343-00 Bottles of 1000 tablets  (relabeled from NDC 43547-354-11)\n                  \n                     30 mg Tablets:red, capsule-shaped tablets, imprinted with ‘H 148’ on one side and plain on the other side.\n\n \n                  NDC 76420-344-30 Bottles of 30 tablets, with child-resistant closure (relabeled from NDC 43547-355-03)\n                  NDC 76420-344-60 Bottles of 60 tablets, with child-resistant closure (repackaged from NDC 43547-355-XX)\n                  NDC 76420-344-90 Bottles of 90 tablets, with child-resistant closure (repackaged from NDC 43547-355-XX)\n                  NDC 76420-344-01 Bottles of 100 tablets, with child-resistant closure (relabeled from NDC 43547-355-10)\n                  NDC 76420-344-05 Bottles of 500 tablets (relabeled from NDC 43547-355-50)\n                  NDC 76420-344-00 Bottles of 1000 tablets (relabeled from NDC 43547-355-11)\n                  \n                     40 mg Tablets:yellow, capsule-shaped tablets, imprinted with ‘H 149’ on one side and plain on the other side.\n\n \n                  NDC 76420-345-30 Bottles of 30 tablets, with child-resistant closure ((repackaged from NDC 43547-355-XX)\n                  NDC 76420-345-60 Bottles of 60 tablets, with child-resistant closure (repackaged from NDC 43547-355-XX)\n                  NDC 76420-345-90 Bottles of 90 tablets, with child-resistant closure (repackaged from NDC 43547-355-XX)\n                  NDC 76420-345-01 Bottles of 100 tablets, with child-resistant closure (relabeled from NDC 43547-355-10)\n                  NDC 76420-345-00 Bottles of 1000 tablets (relabeled from NDC 43547-355-11)",
    "adverseReactions": "Lisinopril is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer Lisinopril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor\n \n  [see Warnings and Precautions (5.2)].\n\n \n                  Lisinopril is contraindicated in patients with:\n                  \n                     a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor\n                     hereditary or idiopathic angioedema\n                  \n                  Do not co-administer aliskiren with lisinopril in patients with diabetes\n \n  [see Drug Interactions (7.4)].",
    "ingredients": [
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "LISINOPRIL",
            "code": "E7199S1YWR"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "organization": "Asclemed USA, Inc.",
    "name": "LISINOPRIL",
    "effectiveTime": "20250502"
}